What's New?

The European Hematology Association (EHA) 2025 Annual Congress, held June 12–15 in Milan, Italy, featured over 100 presentations focused on myelodysplastic syndromes (MDS). This year’s research spotlighted promising advances across diagnosis, risk stratification, anemia treatment in lower-risk MDS, strategies for high-risk disease, and transplantation. Notably, new insights into AI-powered diagnostics, the evolving use of imetelstat and luspatercept, and emerging transplant protocols were shared. Explore our full summary for key data and takeaways from featured abstracts that may shape the future of MDS care.

Bone marrow biopsies play a critical role in diagnosing, staging, and monitoring treatment response in AML. In this expert-led educational video, Thomas LeBlanc, MD, MA, MHS, hematologist-oncologist, associate professor of medicine and population health sciences at Duke Cancer Institute, and Keri Halsema, MSN, NP, nurse practitioner and senior instructor in the Cell Therapy Center at University of Colorado, walk through essential best practices for performing and interpreting bone marrow biopsies in AML care. Topics include key diagnostic tests, biopsy techniques, outpatient procedural considerations, and strategies to improve provider confidence through training and simulation. The video also highlights the importance of patient education, interdisciplinary coordination, and timely lab processing to support optimal outcomes.

Research is the pathway towards a cure for MDS. From May 30 to June 3, 2025, doctors from around the world met to talk about new treatments at the annual meeting of the American Society of Clinical Oncology (ASCO).

Dr. Goldberg has prepared an easy-to-understand summary of the key MDS studies presented.

The MDS Foundation is proud to expand its Journey of Empowerment (JOE) initiative to the acute myeloid leukemia (AML) community - an interactive platform to support patients and caregivers with trusted information, engaging education, and tailored resources. 

Vor Bio has announced the initiation of a process to explore strategic alternatives—including a potential sale, merger, or asset licensing—amid a challenging funding environment. The company will wind down its clinical and manufacturing operations and has implemented a 95% workforce reduction while retaining a core team to support the strategic review.

Taiho Oncology will showcase findings from five studies at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, including two oral presentations. Highlights include data on novel therapies such as an all-oral decitabine-cedazuridine combination for AML, zipalertinib for NSCLC with EGFR exon 20 insertion mutations, and real-world studies on metastatic colorectal cancer and cholangiocarcinoma treatments.

Faron Pharmaceuticals has announced positive topline results from its Phase II BEXMAB trial in treatment-resistant higher-risk myelodysplastic syndrome (HR MDS). The combination of bexmarilimab and azacitidine showed high overall response rates and continued strong tolerability. Full data has been submitted to the 2025 ASCO Annual Meeting, and preparations for a Phase III trial are underway.

Orca Bio reports groundbreaking Phase 3 results from the Precision-T study, showing that its investigational therapy Orca-T significantly improves survival free of chronic graft-versus-host disease compared to traditional allogeneic stem cell transplants in patients with AML, ALL, MDS, and MPAL. The therapy demonstrated a 78% cGvHD-free survival rate at one year, with 94% overall survival. Findings will be presented at the 51^st EBMT Annual Meeting and support Orca Bio’s upcoming FDA submission.